BioVie, Inc. Common Stock
Here’s whether BioVie, Inc. Common Stock (BIVI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); RSI 55 — healthy momentum range; strong 1-year return of +28.3%; 3-month momentum positive (+28.3%); rising volume confirms the move (2.82x 30d avg). Concerns: 50-day MA is falling (-2.14% over 10 days). Currently 48.5% off its 52-week high. Score: +6/7.
BIVI is in a confirmed uptrend, trading above both its 50-day ($1.66) and 200-day ($1.46) moving averages. An RSI of 54.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +28.3% compares to +20.5% for SPY (beat the market by 7.8%). The current 48.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.